PBAC to review opioid prescribing

March date set for new report on 'all strengths and all brands'
Opioids

The prescribing of every single brand and strength of opioid funded by taxpayers will be reviewed by a PBAC expert committee over the next two months.

The Drug Utilisation Subcommittee (DUSC), which conducts post-marketing reviews for the PBAC, has been commisioned to write up the wide-ranging report.